Brain injection aims to slow Huntington's
NCT ID NCT05541627
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a gene therapy called AB-1001 in 5 adults with early Huntington's disease. The treatment is injected directly into the brain to potentially slow the disease. The main goal is to check safety, but researchers will also look at brain changes on MRI and symptom progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut du Cerveau (ICM), Hôpital La Pitié Salpêtrière APHP
Paris, Île-de-France Region, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a genetic 'Patch' fix Huntington's disease? lab test aims to find out
- Could a brain disease change behavior years before diagnosis?
- Scientists decode gait signatures to spot brain diseases
- Can a One-Page guide spark better End-of-Life talks for dementia patients?
- Blood test could spot Parkinson's earlier, study hopes
- Can a cooking oil protect the brain in Huntington's?